$14,590.64 consulting Payment -- Boehringer Ingelheim to Dr. Susan Taylor

Boehringer Ingelheim pays Internal Medicine physician $14,590 for Kisqali consulting

This page provides a detailed analysis of a $14,590.64 consulting payment from Boehringer Ingelheim to Dr. Susan Taylor. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$14,590.64
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyBoehringer Ingelheim
PhysicianDr. Susan Taylor
NPI Number1060464831
Physician SpecialtyInternal Medicine
LocationCity, WA
Date of Payment2024-04-24
Related Drug/DeviceKisqali
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Boehringer Ingelheim made a $14.6K consulting payment to Susan Taylor, a Internal Medicine specialist in City, WA. The payment was associated with Kisqali. The payment of $14,590.64 to Dr. Susan Taylor for consulting services related to Kisqali is a significant amount for a single payment. Boehringer Ingelheim made this payment, indicating a focus on their drug Kisqali. The payment was made on April 24, 2024, suggesting recent engagement between the pharma company and the physician.

Patient Guidance: What This Payment Means for You

This payment was for consulting services related to the drug Kisqali. Discuss with your doctor if this drug is relevant to your treatment plan. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees can vary widely, but $14,590.64 for a single engagement is on the higher end for Internal Medicine physicians, though justifiable for specialized expertise.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for consulting services are permissible under the Sunshine Act, provided they are accurately reported and do not constitute kickbacks.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $14.6K payment for?

This was a consulting payment of $14.6K from Boehringer Ingelheim to Susan Taylor, categorized as "Consulting Fee". It was associated with Kisqali. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Susan Taylor accept pharmaceutical money?

Yes, Susan Taylor received this $14.6K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Susan Taylor's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $14.6K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Internal Medicine?

To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Susan Taylor's relationship with Boehringer Ingelheim?

The payment type is specifically 'consulting', suggesting Dr. Taylor provided expert advice. This $14.6K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Internal Medicine?

The drug associated with the payment is Kisqali, a targeted therapy for breast cancer.

What should patients do after learning about this payment?

This payment was for consulting services related to the drug Kisqali. Discuss with your doctor if this drug is relevant to your treatment plan.

What else should I know about this consulting payment?

The physician's specialty is Internal Medicine, a broad field that often includes oncological care.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.